Robbins Umeda LLP Announces an Investigation of ZOLL Medical Corporation
13 Março 2012 - 3:17PM
Business Wire
Shareholder rights firm Robbins Umeda LLP has commenced an
investigation into possible breaches of fiduciary duty and other
violations of the law by members of the board of directors of ZOLL
Medical Corporation (NASDAQ: ZOLL) in connection with their efforts
to sell the company to Asahi Kasei Corporation. Concerned
shareholders who would like more information about their rights and
potential remedies can contact attorney Gregory E. Del Gaizo at
(800) 350-6003, info@robbinsumeda.com, or via the shareholder
information form on the firm's website.
On March 12, 2012, ZOLL announced that it had entered into a
definitive merger agreement to be acquired by Asahi Kasei
Corporation. According to the terms of the deal, Asahi Kasei
Corporation, through a U.S. subsidiary, will make a cash tender
offer to purchase all of the outstanding shares of ZOLL common
stock for $93.00 per share. The tender offer is expected to
commence within 10 business days and will remain open for a minimum
of 20 business days. The transaction is expected to close in the
second quarter of 2012.
Robbins Umeda LLP's investigation focuses on whether ZOLL's
board is undertaking a fair process to obtain maximum value and
adequately compensate shareholders in light of the company's recent
positive financial results. On January 19, 2012, ZOLL announced
financial results for the first quarter of fiscal year 2012 that
beat analyst expectations. The company reported diluted EPS of
$0.29, a 61% increase compared to the prior year's first quarter
EPS of $0.18 and above analyst estimates of only $0.26.
Additionally, ZOLL reported quarterly revenue of $133.75 million,
an 18% increase compared to the prior year's first quarterly
revenue of $113.63 million and above analyst estimates of only
$132.63 million.
Additionally, at least two market analysts have released target
prices for ZOLL that value the company's stock at $100.00 per
share, significantly higher than the value being offered by Asahi
Kasei Corporation as a part of the proposed transaction.
Robbins Umeda attorneys highlight that ZOLL shareholders have
the option to file a class action lawsuit against the company to
secure the best possible price for the company's shareholders and
the disclosure of material information to shareholders so they can
vote on the transaction in an informed manner.
Robbins Umeda LLP is a nationally recognized leader in
securities litigation and shareholder rights law. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits, and has helped its
clients realize more than $1 billion of value for themselves and
the companies in which they have invested. For more information,
please go to http://www.robbinsumeda.com.
Press release link:
http://www.robbinsumeda.com/shareholders-rights-blog/zoll-medical-corporation/
Attorney Advertising. Past results do not guarantee a similar
outcome.
Zoll (NASDAQ:ZOLL)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Zoll (NASDAQ:ZOLL)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Zoll Medical Corp. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Robbins Umeda LLP